Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 13/20 | 0.83 |
| ▸ | GFER | P55789 | 2/20 | 0.98 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.98 |
| ▸ | RAD52 | P43351 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 9/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.83 |
| ▸ | RECQL | P46063 | 4/20 | 0.83 |
| ▸ | BLM | P54132 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.83 |
| ▸ | THPO | P40225 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.83 |
| ▸ | DRD3 | P35462 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL11215880 | 0.99 | GFER (1.00) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL41213 | 0.99 | GFER (1.00) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL3136078 | 0.94 | GFER (0.91) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL28098126 | 0.93 | GFER (0.88) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL11170039 | 0.91 | GFER (0.86) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL13287212 | 0.91 | DRD1 (1.00) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL1815791 | 0.91 | DRD1 (1.00) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL9157427 | 0.91 | DRD1 (1.00) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL34250 | 0.91 | DRD1 (1.00) | GFERTAAR1RAD52DRD1DRD2 | |
| Fenoldopam SCHEMBL41214 | 0.91 | DRD1 (1.00) | GFERTAAR1RAD52DRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844018-A2 | CRYSTALLINE FORMS FENOLDOPAM MESYLATE | Sicor Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070066594-A1 | Crystalline forms fenoldopam mesylate | SICOR, INC. | 2007-03-22 | — | — | US | claimed |
| WO-2007022173-A2 | CRYSTALLINE FORMS FENOLDOPAM MESYLATE | SICOR, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-1844018-A2 | CRYSTALLINE FORMS FENOLDOPAM MESYLATE | Sicor Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070066594-A1 | Crystalline forms fenoldopam mesylate | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2007022173-A2 | CRYSTALLINE FORMS FENOLDOPAM MESYLATE | SICOR, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066594-A1 | Crystalline forms fenoldopam mesylate | PDE5A, PDE3A, PDE6C | DRD1 2512/4885GFER 1680/4885TAAR1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.